阳光诺和 (688621)
Beijing Sun-Novo Pharmaceutical Research Co., Ltd.
K-Line Chart
No K-line data
Stock Details
1. Key Indicators
- Total Shares(W): 11200.00
- Circulating A-Shares(W): 11200.00
- Earnings Per Share(RMB): 1.4900
- Net Assets Per Share(RMB): 10.3770
- Operating Revenue(W RMB): 85576.33
- Total Profit(W RMB): 16797.92
- **Net Profit Attributable to Parent(W RMB) **: 16328.67
- Net Profit Growth Rate(%): -21.38
- Weighted Return on Equity(%): 14.9500
- Operating Cash Flow Per Share(RMB): 1.3180
- Undistributed Profit Per Share(RMB): 6.3289
- Capital Reserve Per Share(RMB): 3.4997
2. Main Business
The main business covers:
- Innovative drug development
- Generic drug development
- Comprehensive R&D services including consistency evaluation
3. Company Basic Information
- Company Name: Beijing Sun-Novo Pharmaceutical Research Co., Ltd.
- Listing Date: 2021-06-21
- Industry: Pharmaceuticals & Healthcare - Medical Services
- Address: Building 7, No. 79 Shuangying West Road, Changping District Science Park, Beijing
- Website: https://www.sun-novo.com
- Company Profile: Beijing Sun-Novo Pharmaceutical Research Co., Ltd. was established through the overall transformation of Beijing Sun-Novo Pharmaceutical Research Co., Ltd. into a joint stock company. On March 12, 2020, Dahua Certified Public Accountants issued the "Audit Report" (Dahua Audit No. [2020]003271), which showed that as of January 31, 2020, the audited net asset value of Sun-Novo Limited was RMB 118.6643 million. On the same day, Zhongming International Asset Appraisal (Beijing) Co., Ltd. issued the "Asset Appraisal Report" (Zhongming Appraisal No. [2020]16065), which showed that as of the appraisal base date of January 31, 2020, the assessed net asset value of Sun-Novo Limited was RMB 129.2224 million using the asset-based approach. On March 12, 2020, Sun-Novo Limited held a shareholders' meeting and agreed to convert the audited net assets of RMB 118.6643 million as of January 31, 2020 into 60 million shares, with the remaining RMB 58.6643 million included in capital reserve, thereby transforming Sun-Novo Limited into a joint stock company. On the same day, 31 promoters including Li Qian, Liu Yujing, and Kang Yanlong jointly signed the "Promoters Agreement," unanimously agreeing to establish the joint stock company. On March 21, 2020, Dahua Certified Public Accountants issued the "Capital Verification Report" (Dahua Verification No. [2020]000122), confirming that all promoters had fully paid up the total capital contribution of RMB 60 million, with the portion of the audited net assets exceeding RMB 60 million included in capital reserve. On March 21, 2020, the company held its founding meeting and first shareholders' meeting. On March 25, 2020, the Beijing Changping District Market Supervision Administration issued the renewed "Business License" (Unified Social Credit Code: 91110107685771683F) to Sun-Novo after the overall transformation.
4. Top 10 Circulating Shareholders
| Rank | Institution Name | Institution Type | Shares Held (W) | Percentage Held (%) |
|---|---|---|---|---|
| 1 | Wuhan Xinneng Industrial Development Co., Ltd. | General Legal Person | 306.23 | 2.73 |
| 2 | Guangzhou GF Xinde Phase I Health Industry Investment Enterprise (Limited Partnership) | General Legal Person | 219.79 | 1.96 |
| 3 | Rongtong Health Industry Flexible Allocation Mixed Securities Investment Fund Class A | Fund | 200.00 | 1.79 |
| 4 | Hong Kong Securities Clearing Company Ltd. | Northbound Funds | 178.77 | 1.60 |
| 5 | Hangzhou Kaitai Minde Investment Partnership (Limited Partnership) | General Legal Person | 144.17 | 1.29 |
| 6 | Anxin Pharmaceutical Health Theme Stock Initiated Securities Investment Fund Class A | Fund | 137.98 | 1.23 |
| 7 | E Fund Health Excellence Hybrid Securities Investment Fund Class A | Fund | 42.76 | 0.38 |
| 8 | Tianhong Medical Health Hybrid Securities Investment Fund Class A | Fund | 32.96 | 0.29 |
| 9 | Huafu Health Culture Flexible Allocation Hybrid Securities Investment Fund Class A | Fund | 18.00 | 0.16 |
| 10 | Nuoan Theme Selection Hybrid Securities Investment Fund | Fund | 12.01 | 0.11 |
5. Concept Sectors
- Immunotherapy
- Artificial Intelligence
- Generic Drugs
- CXO Concept
- Hepatitis Concept
- Innovative Drugs
- Weight Loss Drugs
- Pet Economy
- Margin Trading & Securities Lending
- High-Performance Stocks
- Private Placement Plan
- Restructuring Plan
- Intensive Research
- Specialized, Refined, Special and New Enterprises
- Special Loans
- CSI Repurchase
- STAR 200
- SSE 580
Remarks
- Data update date: 2025-09-30
- Data source: Public Market Information